Advertisement
Screener

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Proceeds from Convertible Debt

2.8 / 5 stars · 68/120 Roast Me

ADAPTIVE BIOTECHNOLOGIES CORPORATION Proceeds from Convertible Debt

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Proceeds from Convertible Debt of $335.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromConvertibleDebt · last filed 2026-08-04

  • 2026-06-30: Proceeds from Convertible Debt 6 month $335.51M.
  • 2025-06-30: Proceeds from Convertible Debt 6 month $0.00.
Period endProceeds from Convertible Debt 6 month
2026-06-30$335.51M
10-Q · filed 2026-08-04
2025-06-30$0.00
10-Q · filed 2026-08-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Greenland Mines Ltd (GRML)United States$2.362B